Clinical Research Directory
Browse clinical research sites, groups, and studies.
Phase Ia/Ib Trial of SCTA02A Injection in Healthy Adults and Patients With Chronic Hepatitis B
Sponsor: Sinocelltech Ltd.
Summary
Study SCTA02A-A101 is designed to assess the safety, tolerability and pharmacokinetics of SCTA02A in healthy volunteers and participants with chronic hepatitis B virus infection. Eligible participants will receive study treatment in this phase 1 dose-escalation study. All treated patients will also undergo a safety follow-up period after last study drug administration.
Official title: A Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Phase Ia/Ib Trial to Evaluate the Safety, Tolerability, and Pharmacokinetic Profile of SCTA02A Injection in Healthy Adults and Patients With Chronic Hepatitis B
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
60
Start Date
2026-10
Completion Date
2027-12
Last Updated
2026-10-29
Healthy Volunteers
Yes
Conditions
Interventions
SCTA02A
SCTA02A, an investigational monoclonal antibody.
Placebo
Placebo
Locations (1)
Beijing Friendship Hospital, Capital Medical University
Beijing, Beijing Municipality, China